{
    "nctId": "NCT01654367",
    "briefTitle": "Research of Zoledronic Acid and Aromatase Inhibitors as Adjuvant Therapy to Breast Cancer",
    "officialTitle": "The Effectiveness and Safety of Treating Operable Breast Cancer by the Adjuvant Therapy of Zoledronic Acid and Aromatase Inhibitors and/or Ovarian Function Inhibition",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2, PHASE3",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 300,
    "primaryOutcomeMeasure": "therapeutic assessment",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Karnofsky\u226570\n2. Provision of informed consent\n3. Pathological confirmation of breast cancer\n4. Hormone receptor-positive and accept aromatase inhibitors for adjuvant endocrine therapy\n5. Not previously received treatment with bisphosphonate\n6. Laboratory criteria:\n\n   PLT\u2265100\\*109/L WBC\u22654000/mm3 HGB\u226510g/dl GOT,GPT,ALP\u22642\\*ULN TBIL,DBIL,CCr\u22641.5\\*ULN\n7. Surgery , radiotherapy and chemotherapy has finished\n\nExclusion Criteria:\n\n1. Pregnant of lactation woman\n2. History of organ transplantation\n3. With mental disease\n4. With severe infection or active gastrointestinal ulcers\n5. With severe liver disease (such as cirrhosis), kidney disease, respiratory disease or diabetes\n6. Disease-free period of other malignant tumor is less than 5 years(except cured basal cell skin cancer and cervical carcinoma in situ)\n7. With heart disease\n8. Experimental drug allergy",
    "sex": "FEMALE",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}